Related Experiment Videos
Translational research studies of erbB oncogenes: selection strategies for breast cancer treatment
B H Brandt1, A Beckmann, F Gebhardt
1Institut für Klinische Chemie und Laboratoriumsmedizin, Westf. Wilh.-Universität Münster, Germany. brandt@uni-muenster.de
Abstract:
Specific gene families, e.g. encoding members of signal transduction pathways, show a gene dosage sensitivity. We report on the determination of the gene dosages of egfr and c-erbB-2 in relation to the intratumoral concentration of the tyrosine kinase receptor protein EGFR and p185c-erbB-2 and the clinical outcome of breast cancer patients in a retrospective study. Prognostic unfavorable subgroups were determined in a life-table analysis by (a) an average gene copy number of egfr of less than 0.4 and greater than 1.6 and an intratumoral EGFR concentration of more than 56 fmol/mg, (b) an intratumoral p185c-erbB-2 concentration above 26 HNU/mg and (c) a quotient of egfr and c-erbB-2 average gene copy numbers of less than 0.15 and greater than 4.35.
Insights
Gene copy numbers for EGFR and c-erbB-2 impact breast cancer patient outcomes. Specific gene dosages and protein concentrations correlate with prognosis, identifying unfavorable subgroups for targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Gene dosage sensitivity affects specific gene families, including those in signal transduction pathways.
- Epidermal Growth Factor Receptor (EGFR) and c-erbB-2 are key tyrosine kinase receptors in cancer.
Purpose of the Study:
- To determine the gene dosages of EGFR and c-erbB-2.
- To correlate gene dosages with intratumoral protein concentrations of EGFR and p185c-erbB-2.
- To analyze the relationship between these factors and clinical outcomes in breast cancer patients.
Main Methods:
- Retrospective study design.
- Determination of gene dosages for EGFR and c-erbB-2.
- Measurement of intratumoral EGFR and p185c-erbB-2 protein concentrations.
- Life-table analysis for prognostic subgroup identification.
Main Results:
- Unfavorable prognostic subgroups identified by specific EGFR gene copy number ranges ( < 0.4 and > 1.6) combined with high intratumoral EGFR concentration (> 56 fmol/mg).
- High intratumoral p185c-erbB-2 concentration (> 26 HNU/mg) indicated a poor prognosis.
- Specific quotients of EGFR and c-erbB-2 gene copy numbers (< 0.15 and > 4.35) were associated with unfavorable outcomes.
Conclusions:
- EGFR and c-erbB-2 gene dosages and protein levels are significant prognostic indicators in breast cancer.
- Identifying these molecular subgroups can aid in risk stratification and treatment decisions.
- Further research into targeted therapies based on these genetic and protein markers is warranted.